Adoptive T cell transfer augments IL-2 mediated tumour regression in a HNSCC xenograft nude mouse model

Cancer Letters

Volumn 272, Issue 2, 2008, Pages 316-324

  Ambade, Aditya ^a   Mulherkar, Rita ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Adoptive T cell transfer; Gene therapy; Head and neck squamous cell carcinoma; IL 2; Xenograft nude mouse model

Indexed keywords

ALPHA2 INTEGRIN; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD69 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; PLASMID DNA;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; CELL LABELING; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOMEGALOVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE THERAPY; HEAD AND NECK CARCINOMA; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE MIGRATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TUMOR REGRESSION; TUMOR XENOGRAFT;

ADOPTIVE TRANSFER; ANIMALS; CARCINOMA, SQUAMOUS CELL; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICE; MICE, NUDE; PLASMIDS; T-LYMPHOCYTES; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; MUS MUSCULUS;

EID: 55949117202     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.07.023     Document Type: Article

References (35)

1. Edwards B.K., Brown M.L., Wingo P.A., Howe H.L., Ward E., Ries L.A., Schrag D., Jamison P.M., Jemal A., Wu X.C., Friedman C., Harlan L., Warren J., Anderson R.N., and Pickle L.W. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J. Natl. Cancer Inst. 97 (2005) 1407-1427
2. Kurkure A.P., and Yeole B.B. Social inequalities in cancer with special reference to South Asian countries. Asian Pac. J. Cancer Prev. 7 (2006) 36-40
3. Gleich L.L. Gene therapy for head and neck cancer. Laryngoscope 110 (2000) 708-726
4. Lamont J.P., Nemunaitis J., Kuhn J.A., Landers S.A., and McCarty T.M. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann. Surg. Oncol. 7 (2000) 588-592
5. Clayman G.L., Frank D.K., Bruso P.A., and Goepfert H. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin. Cancer Res. 5 (1999) 1715-1722
6. O'Malley Jr. B.W., Li D., McQuone S.J., and Ralston R. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. Laryngoscope 115 (2005) 391-404
7. Nemunaitis J., Khuri F., Ganly I., Arseneau J., Posner M., Vokes E., Kuhn J., McCarty T., Landers S., Blackburn A., Romel L., Randlev B., Kaye S., and Kirn D. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19 (2001) 289-298
8. S.A. Rosenberg, M.T. Lotze, L.M. Muul, S. Leitman, A.E. Chang, S.E. Ettinghausen, Y.L. Matory, J.M. Skibber, E. Shiloni, J.T. Vetto, et al., Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N. Engl. J. Med. 313 (1985) 1485-1492.
9. Gaffen S.L., and Liu K.D. Overview of interleukin-2 function, production and clinical applications. Cytokine 28 (2004) 109-123
10. Roth C., Rochlitz C., and Kourilsky P. Immune response against tumors. Adv. Immunol. 57 (1994) 281-351
11. (+) T-cell immunity and NK activity. Cancer Gene Ther. 8 (2001) 321-332
12. Fearon E.R., Pardoll D.M., Itaya T., Golumbek P., Levitsky H.I., Simons J.W., Karasuyama H., Vogelstein B., and Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60 (1990) 397-403
13. O'Malley Jr. B.W., Sewell D.A., Li D., Kosai K., Chen S.H., Woo S.L., and Duan L. The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer. Mol. Endocrinol. 11 (1997) 667-673
14. Thomas S.M., Naresh K.N., Wagle A.S., and Mulherkar R. Preclinical studies on suicide gene therapy for head/neck cancer: a novel method for evaluation of treatment efficacy. Anticancer Res. 18 (1998) 4393-4398
15. Wagle A.S., V Joshi G., Naresh K.N., and Mulherkar R. Preclinical studies for gene therapy of head and neck cancers using the HSV-tk/GCV strategy. Indian J. Biotechnol. 4 (2005) 82-87
16. Veelken H., Re D., Kulmburg P., Rosenthal F.M., Mackensen A., Mertelsmann R., and Lindemann A. Systematic evaluation of chimeric marker genes on dicistronic transcription units for regulated expression of transgenes in vitro and in vivo. Hum. Gene Ther. 7 (1996) 1827-1836
17. Mulherkar R., Goud A.P., Wagle A.S., Naresh K.N., Mahimkar M.B., Thomas S.M., Pradhan S.A., and Deo M.G. Establishment of a human squamous cell carcinoma cell line of the upper aero-digestive tract. Cancer Lett. 118 (1997) 115-121
18. Kokkinopoulos D., Perez S., Sotiriadou R., Stinios J., and Papamichail M. The use of nylon wool for the isolation of T lymphocyte subpopulations. J. Immunol. Methods 154 (1992) 1-6
19. Lyons A.B. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J. Immunol. Methods 243 (2000) 147-154
20. Chang C.Y., Lee J., Kim E.Y., Park H.J., Kwon C.H., Joh J.W., and Kim S.J. Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model. BMC Cancer 7 (2007) 87
21. Collinet P., Vereecque R., Sabban F., Vinatier D., Leblanc E., Narducci F., Querleu D., and Quesnel B. In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice. J. Obstet. Gynaecol. Res. 32 (2006) 449-453
22. Shi F., Rakhmilevich A.L., Heise C.P., Oshikawa K., Sondel P.M., Yang N.S., and Mahvi D.M. Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model. Mol. Cancer Ther. 1 (2002) 949-957
23. Soler M.N., Bobe P., Benihoud K., Lemaire G., Roos B.A., and Lausson S. Gene therapy of rat medullary thyroid cancer by naked nitric oxide synthase II DNA injection. J. Gene Med. 2 (2000) 344-352
24. Mincheff M., Tchakarov S., Zoubak S., Loukinov D., Botev C., Altankova I., Georgiev G., Petrov S., and Meryman H.T. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur. Urol. 38 (2000) 208-217
25. Maruyama H., Sugawa M., Moriguchi Y., Imazeki I., Ishikawa Y., Ataka K., Hasegawa S., Ito Y., Higuchi N., Kazama J.J., Gejyo F., and Miyazaki J.I. Continuous erythropoietin delivery by muscle-targeted gene transfer using in vivo electroporation. Hum. Gene Ther. 11 (2000) 429-437
26. Fong C.L., Mok C.L., and Hui K.M. Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression. Gene Ther. 13 (2006) 245-256
27. Morini M., Albini A., Lorusso G., Moelling K., Lu B., Cilli M., Ferrini S., and Noonan D.M. Prevention of angiogenesis by naked DNA IL-12 gene transfer: angioprevention by immunogene therapy. Gene Ther. 11 (2004) 284-291
28. Smyth M.J., Kershaw M.H., Darcy P.K., and Trapani J.A. Adoptive transfer: the role of perforin in mouse cytotoxic T lymphocyte rejection of human tumor xenografts in vivo. Xenotransplantation 5 (1998) 146-153
29. Topalian S.L., and Rosenberg S.A. Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2. Acta Haematol. 78 Suppl. 1 (1987) 75-76
30. Okada K., Nannmark U., Vujanovic N.L., Watkins S., Basse P., Herberman R.B., and Whiteside T.L. Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer. Cancer Res. 56 (1996) 1599-1608
31. + regulatory T cells increases bacterial clearance and improves survival in polymicrobial sepsis. J. Immunol. 174 (2005) 7141-7146
32. Fujita K., Ikarashi H., Takakuwa K., Kodama S., Tokunaga A., Takahashi T., and Tanaka K. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin. Cancer Res. 1 (1995) 501-507
33. Paciucci P.A., Holland J.F., Glidewell O., and Odchimar R. Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2-activated cells in patients with advanced cancer. J. Clin. Oncol. 7 (1989) 869-878
34. Valmori D., Pittet M.J., Rimoldi D., Lienard D., Dunbar R., Cerundolo V., Lejeune F., Cerottini J.C., and Romero P. An antigen-targeted approach to adoptive transfer therapy of cancer. Cancer Res. 59 (1999) 2167-2173
35. Velilla P.A., Shata M.T., Lages C.S., Ying J., Fichtenbaum C.J., and Chougnet C. Effect of low-dose IL-2 immunotherapy on frequency and phenotype of regulatory T cells and NK cells in HIV/HCV-coinfected patients. AIDS Res. Hum. Retroviruses 24 (2008) 52-61